Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belimumab
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Belimumab is a fully human recombinant IgG1λ monoclonal antibody used as an add-on therapy for systemic lupus erythematosus (SLE) and active lupus nephritis in adults and children aged 5 years and older. It works by selectively binding to and inhibiting the B-lymphocyte stimulator protein (BLyS, also known as BAFF or TNFSF13B), a key factor in B cell survival. By blocking BLyS, belimumab reduces the survival of autoreactive B cells, promotes their apoptosis, and decreases differentiation into immunoglobulin-producing plasma cells. This mechanism helps reduce chronic inflammation and tissue damage associated with SLE. Belimumab was developed by Human Genome Sciences (now part of GSK) and is marketed under the brand name Benlysta[1][2][6][8].
- Brand names
- Benlysta
- Other names
- LymphoStat-B
02
Targets
BAFF (Tumor necrosis factor ligand superfamily member 13B)
Beyond the preview
Go deeper on belimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belimumab.